News on CML -Archives 2019-2018 -Chronic myeloid leukemia

                  See News on CML (after 2020)
                  See Archives ( 2017-2016)
                  See Archives ( 2015-2014)
                  See Archives ( 2013-2012)
                                 See Archives ( 2011 and before)

​
​
Chronic myeloid leukaemia: The dangers of not knowing your BCR-ABL1 transcript
December 2019, Leukemia Research

Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study.
December 26, 2019,  PubMed

Living a happy life with leukaemia
December 25, 2019, BBC News

Cost Effectiveness of Therapeutic Drug Monitoring for Imatinib Administration in Chronic Myeloid Leukemia
December 25, 2019, docwire

Super-Enhancer-Associated Hub Genes In Chronic Myeloid Leukemia Identified Using Weighted Gene Co-Expression Network Analysis
December 23, 2019, Dovepress

Do persons with chronic myeloid leukaemia have normal or near normal survival?
December 20, 2019,  Leukemia

Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP
December 20, 2019,  ASH Publications

Getting CML Patients Into a Deeper Treatment Response VIDEO
December 20, 2019,  Patient Power

Nilotinib Therapy Plus Peg-IFN Feasible, Effective for BCR-ABL1–Positive CML
December 20, 2019, Oncology Learning Network
 
Despite lower price of generic imatinib, overall costs for chronic myeloid leukemia remain high
December 20, 2019,  HemOncToday       

Update on stopping CML treatment: Report from the American Society of Hematology Congress 2019
December  20, 2019, CML Advocates Network

Massimo Breccia, ASH 2019: Chronic Myeloid Leukemia Patients after Discontinuation   VIDEO
December 18, 2018, Touch Medical Media

Wichita Falls native in remission uses cancer journey to help others
December 14, 2019, Texomas Homepage

Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy
December 13, 2019, Dovepress

CML Patient Views on Psychological Support During Treatment-Free Remission
December 13, 2019, Journal of Clinical Pathways

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
December 12, 2019, The New England Journal of Medicine

Step forward in leukemia treatment
December 12, 2019, South Australian Health and Medical Research Institute

Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia
December 11, 2019, PubMed

Leukaemia breakthrough as scientists find drug can fight the blood cancer without causing toxic side effects seen in currently-used medications
December 11, 2019, Daily Mail Health

Double standards: The poor may wait for eternity
December 11, 2019, The Express Tribune Health
 
Scientists highlight the benefits of Droplet Digital PCR technology at the 2019 ASH meeting
December 10, 2019, News Medical Life Sciences

Role of cancer immunology in chronic myelogenous leukemia
January 2020, Science direct

 Ascentage Pharma Releases Updated Data of its Novel BCR-ABL Inhibitor, HQP1351, in an Oral Presentation Nominated for "Best of ASH"
December 10, 2019, Biospace

Monitoring Disease Recurrence With Patient-Reported Outcomes After Discontinuation of Tyrosine Kinase Inhibitor Therapy
December 10, 2019,  OncologyNurseAdvisor

A new target for leukaemia patients seeking treatment free remission
December 6, 2019,  SAHMRI

Professor and marathoner helps put blood cancer on the run
December 2, 2019, UAB News

Inhibition of KPNB1 Inhibits Proliferation and Promotes Apoptosis of Chronic Myeloid Leukemia Cells Through Regulation of E2F1
December 2, 2019, Dovepress

Are We Ready To Use Precision Medicine In Chronic Myeloid Leukemia Practice?
December 2019, Haematologica

BCR/ABL1 Transcripts in Healthy Individuals: A Comparative Analysis Between First-Degree Relatives of Patients with Chronic Myelogenous Leukemia and Subjects without Antecedents of the Disease
November, 2019,  PubMed

Our son was born from sperm frozen before I underwent leukaemia treatment
November 30, 2019, The Telegraph

Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase
November 26, 2019, Nature.com

Ireton man's diagnosis changes everything
November 26, 2019, nwestiowa.com
 
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
November 25, 2019, Leukemia
​
Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia
November 23, 2019,  Springer Nature

Longtime cancer researcher Charles Sawyers named first STAT Biomedical Innovation Award winner
November 21, 2019, Stat News

Charles L. Sawyers: Overview -Overcoming Resistance to Molecularly Targeted Cancer Therapy
November 17, 2019, Memorial Sloan Kettering Cancer Center

Health Canada approves two tests for CML patients
November 15, 2018, MDedge

Treatment-Free Remission at Heart of New CML Study
November 14, 2019, AJMC

Ascentage Pharma to Release Updated Data of its Novel, Third-Generation BCR-ABL Inhibitor, HQP1351, in Chinese Chronic Myeloid Leukemia Patients in an Oral Presentation at the 61st American Society of Hematology Annual Meeting
November 14, 2019, PrNewswire
​
Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)
NOVEMBER 13, 2019, Journal Blood

A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib
November 13,  2019, Journal Blood

Effects of Ramadan Fasting in Patients with Chronic Myeloid Leukemia in Chronic Phase
November 13, 2019, Journal Blood

Niagara Falls Boy Battling Leukemia in Need of Our Love & Support
November 13, 2019, The Niagara Reporter

The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt
November 13, 2019, ASH Publications

Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia
November 10, 2019, Inserm

Very late relapse with rapid BCR-ABL1 elevation after more than seven years of treatment-free remission with undetectable molecular residual disease in chronic myeloid leukaemia
November 8, 2019, British Journal of Heamatology

Learning to stop cancer at its roots
November 7, 2019, Medical Xpress

New approaches to molecular monitoring in CML (and other diseases)
November 7, 2019, Blood

Acquired von Willebrand Syndrome in Pediatric Patients With Chronic Myeloid Leukemia
November 7, 2019, Hematology Advisor

UCLA Health partners with Kareem Abdul-Jabbar on health and wellness
November 6, 2019, UCLA

CVS' app for specialty drug adherence is yielding positive results for patients
November 6,  2019, Business Insider

Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1–2 safety and feasibility study
November 6, 2019, The Lancet Heamatology

Improving Treatment Adherence Through a CML Specialty Pharmacy Service Model
November 5, 2019, Journal of Clinical Pathways

OHSU 'absolutely closer' to cure for cancer after Gert Boyle’s $100 million donation
November 4, 2019, KGW8

How CVS is using digital tools to boost specialty pharmacy adherence
November 4, 2019, Fierce Healthcare

MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia
November 2019, Haematologica
 
Atypical chronic myeloid leukemia achieving good response with azacytidine
October 2019, PubMed

Selecting, Switching, and Discontinuing First-Line TKIs in CML
October 2019, Oncology Learning Network

Precision Medicine Leader recognised with Ramaciotti Medal of Excellence
October 31, 2019, SAHMRI

Laird G. Jackson, 89, a medical geneticist before the specialty even existed
October 28, 2019, The Philadelphia Inquirer

Blood drive at Metro East school dedicated to principal with cancer
October 28, 2019, FOX2Now

Maintenance tyrosine kinase inhibitors following allo-HCT for chronic myeloid leukemia: A CIBMTR Study
October 25, 2019, PubMed  

VTE Risk and Incidence in Hospitalized Patients With Blood Cancers
October 25, 2019, Cancer therapy advisor

Adherence to Other Oral Medications Declines Following Introduction of Oral Oncolytics
October 25, 2019, Oncology Nurse Advisor

Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitor
October 24, 2019, PubMed

Leukemia Treatment Regimens: Chronic Myeloid Leukemia (CML)
October 23, 2019, Cancer Therapy Advisor

Researchers find potential new treatment for chronic myeloid leukemia
October 23, 2019,  Daily Bruin

Four-year-old Jaguar at Abilene Zoo diagnosed with rare form of cancer
October 23rd 2019, ktxs

Follow-Up Results of Low-Dose Dasatinib for Chronic-Phase Chronic Myeloid Leukemia
October 22, 2019, Journal of Clinical Pathways

Follow-Up Results of Low-Dose Dasatinib for Chronic-Phase Chronic Myeloid Leukemia
October 18, 2019, Cancer Therapy Advisor

Increased Risk of Chronic Myeloid Leukemia Following Gastric Conditions Indicating Helicobacter pylori Infection: A Case-Control Study
October 16, 2019, PubMed
 
Some Say a Nonprofit Research Group Unfairly Influences Drug Prices
October 16, 2019, Nextavenue

Antibody eradicates leukemia stem cells
October 15, 2019, UCLA

Chronic myelogenous leukemia stem cells require cell-autonomous pleiotrophin signaling
October 15, 2019, JCI

Generic Imatinib Comparable to Original in Treatment of Chronic Myeloid Leukemia
October 11, 2019,  Oncology Nurse Advisor

Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management
October 7, 2019, Acta Haematologica

Novartis Is Losing The Leadership In ALL And CML
October 3, 2019, Seeking Alpha

My Husband's Cancer Diagnosis Didn't Stop Us From Growing Our Family
October 3, 2019, Bridox.com

WWE partners with Leukemia & Lymphoma Society (LLS) to help cancer patients and families
October 3, 2019, WWE.com
​
Cepheid Receives FDA Clearance for Xpert® BCR-ABL Ultra Test
October 2, 2019, Yahoo Finance

Blast count prognostic for CML presenting in advanced phase
September 26, 2019, Medical Xpress

Update on Dasatinib Use in Chronic‐phase Chronic Myeloid Leukemia
September 25, 2019, docwire

Comparing Third-Line TKIs for the Treatment of Refractory CML
September 23, 2019, Journal of Clinical Pathways   

Leukemia drug shows promise for treating a childhood brain cancer - nilotinib
September 20, 2019,  Medical Xpress

Weighing Risks and Benefits With the Use of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
September 20, 2019, Targeted Oncology
 
Expert Highlights Frontline Advancements in Treatment Landscape for CML
September 19, 2019, Targeted Oncology

Dr. Seet on Aspects of Treatment Discontinuation in CML
September 17, 2019, , OncLive
              
Prolonged Treatment Free Remission In Chronic Myeloid Leukemia Patients With Previous BCR-ABL1 Kinase Domain Mutations
September 17,  2019, Haematologica

Outcome of Pregnancy in CML Patients in Chronic Phase with Different Molecular Response, Single Centre Experience
September 17, 2019, docwirenews

Study Compares Quality of Life for Patients With Chronic Myeloid Leukemia Treated With Dasatinib vs Imatinib
September 16, 2019, Oncology Nurse Advisor

Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation
September 15, 2019, PubMed

The 2019 Goldman Prize is awarded to Professor François-Xavier Mahon
September 2019, iCMLf

Iron and leukemia: new insights for future treatments
September 13, 2019, Journal of Experimental & Clinical Cancer Research

Prognostic Impact of Additional Chromosomal Abnormalities in Egyptian Chronic Myeloid Leukemia Patients
September 13, 2019, docwire

Management of Advanced Phase Chronic Myeloid Leukemia
September 11, 2019, DocWire Conference Coverage
 
Primary Results of the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase (CP) Chronic Myeloid Leukemia (CML)
September 11, 2019, DocWire News Featured Reading

Weeks after being diagnosed with leukemia, Westhill linebacker plays in season opener
September 10, 2019, syracuse.com

Weeks after being diagnosed with leukemia, Westhill linebacker plays in season opener
September 10, 2019, Syracuse.com

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
September 4, 2019, PubMed

BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits pre-clinical activity in Philadelphia chromosome-positive leukemia
September 4, 2019, PubMed

Emergence role of nucleated red blood cells in molecular response evaluation for chronic myeloid leukemia
September 3, 2019, Dovepress

Outcomes With Nilotinib for Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
September 3, 2019, Hematology Advisor

Discontinuation Of Tyrosine Kinase Inhibitors In Patients With Chronic Myelogeneous Leukemia – You Can Do This At Home If You Read The Instructions
August 2019, Haematologica

Could Flumatinib Replace Gleevec in Chronic-Phase Chronic Myeloid Leukemia?
August 31,2019, CancerConnect

Dr. Cortes on the 192-Week Follow-Up Results of the ENESTop Trial in CML   VIDEO
August 30, 2019, OncLive

Dr. Daver Compares Toxicity Profiles of TKIs in CML
August 29, 2019, OncLive

Tyrosine Kinase Inhibitor Dosing Patterns in Elderly Patients With Chronic Myeloid Leukemia.
August 29, 2019, PubMed

Dr. Seet on the Need for Long-Term Outcome Data Regarding Treatment Discontinuation in CML
August 27, 2019, OncLive

Skin lesions in chronic myeloid leukemia patients during dasatinib treatment
August 26, 2019, Dovepress

Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
August 21, 2019, ClinicalTrials.org

Some Discrepancies Seen Between Real-Life and Guideline-Recommended Care of Chronic Myeloid Leukemia
August 20, 2019, OncologyNurseAdvisor

An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States
August 19, 2019, PubMed

An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States
August 19, 2019,    PubMed

10-Year OS After Bone Marrow Transplantation for CML Similar With/Without Prior TKI Therapy
August 16, 2019, Oncology Nurse Advisor

Leukemia researcher Dr. Jerry Radich receives Kurt Enslein Endowed Chair
August 15, 2019,  Fred Hutch

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
August 13, 2019, Frontiers in Oncology

The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia
August 12, 2018,  PubMed

CML Paradigm Transforms With New Treatments, Potential for TKI Discontinuation
August 9, 2019, OncLive

How to Select the Optimal BCR-ABL TKI Therapy for Treatment of Chronic-Phase CML
August 7, 2019, OncologyNurseAdvisor

New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia
August 6, 2019, Frontiers in Oncology

Challenges in Management of Chronic Phase CML
August 5, 2019, Targeted Oncology

Four Approved Frontline Treatments Benefit Patients with Chronic Myeloid Leukemia
August 2, 2019, Targeted Oncology

Combined inhibition of MDM2 and Bcr-Abl tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model
August 2019, Haematologica

Leukemia and Childhood Infection Hypothesis
Jul 30, 2019 ,News Medical

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
July 27, 2019, Cancer medicine

Comorbidities Can Affect CML Treatment Decisions
July 25, 2019, Oncology Nursing News

Ep. 147: “Targeted Repair in Blood Stem and Progenitor Cells” Featuring Dr. Jennifer Adair
July 23, 2019, The stem cell podcast

Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL
July 22, 2019, Dovepress
​
Ascentage Pharma to Initiate Phase Ib Study of HQP1351 in Tyrosine Kinase Inhibitors -resistant Chronic Myeloid Leukemia Patients in the US
July 22, 2019, Biospace
 
Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML
July 17, 2019, Frontiers

TKI Dose Reduction Improves Treatment-Free Remission Protocols for Chronic Myeloid Leukemia
July 17, 2019, Oncology Nurse Advisor

Expert Discusses Benefits of Identifying Mutations in CML with NGS Testing
July 15, 2019. Targeted Oncologyy   

Role of Ponatinib in Treatment of R/R CML
July 15, 2019, Targeted Oncology

Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase
June 14,2019, PubMed

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
July 12, 2019, Newswise

Determining predictors of long-term survival in imatinib-treated chronic myeloid leukemia (CML)
July 11, 2019, LLS Community

Philanthropic Competition Unleashes the Power of Turning Grief into Passion
July 10, 2019, Yahoo  finance

University Hospitals Doctor Explains Myeloid Leukemia, Outlook for Carrasco
July 9, 2019.  ideatream

Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission
July 9, 2019, Cancer Medicine

Clinical Challenge: Discontinuing TKIs in Chronic Phase CML
July 7, 2019, MedPageToday

Cleveland Indians identify Carlos Carrasco’s illness as chronic myeloid leukemia
July 7, 2019, cleveland.com

Dasatinib shows promise as a control agent for CAR T cells
July 5, 2019, MDedge

Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
July 4, 2019, PubMed

Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome
July 4, 2019, PubMed

SIRT1 Plays Key Role in Preventing Leukemia Stem Cell Elimination
July 4, 2019, AJMC
 
Monitoring in CML Remains Imperative as TKI Cessation Rises to the Forefront of Care
July 3, 2019, OncLive
 
Fred Hutch global health research honored for impact, collaboration
July 2, 2019, Fred Hutch

TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS HARBORING ATYPICAL BCR-ABL1 TRANSCRIPTS
June 2019, Hemasphere

Treatment Value of Second-Generation TKIs for Patients With CML
June 28, 2019, Journal of Clinical Pathways

First case report of latent tuberculosis reactivation complicating treatment with nilotinib in chronic myeloid leukemia
Jun 25, 2019, Synapse.

How Precision Medicine Is Changing Cancer Treatment
June 24, 2019, nextavenue

A Glossary of Cancer Terms for Patients
June 21, 2019, Cancer Therapy Advisor

Breaking News from EHA 2019 in Amsterdam
June 20, 2019, Docwire

Negative MR4·0 chronic myeloid leukaemia and its possible implications for treatment‐free remission
June 19, 2019, British Journal of Hematology

Patient Perspectives: Closing the Gap of Racial Disparity in Chronic Myeloid Leukemia   
June 19, 2019, Specialty Pharmacy Times

Life’s work of talented B.C. sculptor leads to leukemia
June 18, 2019, Coast Mountain News

Nilotinib Benefits Relapsed Patients With CML After Treatment Discontinuation
June 18, 2019, Targeted Oncology

Rare cancer strikes young Flathead girl
June 16, 2019, Montana News

Is There a Role for Dose Modification of TKI Therapy in CML
June 14, 2019,  Current Hematologic Malignancy Reports

Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report   
June 14, 2019, Clinical case reports         

Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study
June 14, 2019, PubMed

Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study
June 14, 2019, The Lancet

Study Finds Women With Rare Bone Marrow Cancer Can Still Have Safe Childbirth
June 14, 2019, docwire

Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna® use and promising combination data with investigational compound asciminib (ABL001)
June 14, 2019, Globe News Wire

SIRT1 plays key role in chronic myeloid leukemia by aiding persistence of leukemic stem cells
June 10, 2019, UAB News

Diamonds Are Forever, but TKIs in CML Don't Have to Be
June 6, 2019, Medscape Medical News

The molecular mechanisms underlying BCR/ABL degradation in chronic myeloid leukemia cells promoted by Beclin1-mediated autophagy
June 6, 2019, DovePress

TKI Discontinuation Still an Unclear Picture in CML
June 6, 2019, OncLive

An alternative way – tyrosine kinase inhibitor (TKI) de-escalation – to discontinue TKIs in order to achieve treatment-free remission
June 5, 2019, Expert Review of Hematology               

Budget Impact of Treatment-Free Remission in Treating Chronic-Phase Philadelphia-Positive Chronic Myeloid Leukemia in Lebanon
June 5, 2019, PubMed
 
Efficacy of Bosutinib in Chronic Myeloid Leukemia Resistant to Prior Treatment
June 5, 2019, Hematology Advisor
 
Treatment-Free Remission After Nilotinib May Be Durable in Chronic Myeloid Leukemia
June 3, 2019, Hematology Advisor

Flumatinib Shows Promise in Chronic-Phase Chronic Myeloid  Leukemia
June 2, 2019, Cancer Therapy Advisor
 
Flumatinib Superior to Imatinib in Chronic Myeloid Leukemia
June 1, 2019, ASH Clinicals News

Case 1: TKI Therapy in CP-CML             VIDEO
May 28, 2019, Targeted Oncology

FDA Should Reassess Postmarket Trials for Cancer Drugs Approved via Accelerated Pathway, Researchers Say
May 28, 2019, Raps
​​​
ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL)
May 26, 2019,  Journal of Clinical Oncology

Chronic myeloid leukemia stem cells
May 24, 2019, Leukemia

Rates of Transcript Variants in Chronic Myeloid Leukemia Associated With Sex and Age
May 22, 2019, Hematology Advisor

Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia
May 15, 2019,  Current Medical Research and Opinion

Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis
May  14, 2019,  Frontiers  in Oncology    

Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis
May 14, 2019, PubMed

Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy Cessation
May 13, 2019, PubMed

Lawsuit accuses Teva of working with other drug firms to inflate prices
May 11, 2019, AXIOS

Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life
May 11, 2019, PubMed

10 Things People Don’t Realize You’re Doing Because You Have An Invisible Illnes
May 10, 2019, Thought Catalog

The silent affordability crisis facing sick people
May 8, 2019, Axios

Muscle Complaints Are a Frequent Side Effect of TKI Use in CML, but What Causes Them?
May 7, 2019, Cancer therapy advisor  

Next-Generation Sequencing Detects Early Kinase Domain Mutations in Patients With CML
May 6, 2019, Oncology Learning Network

Predictors of TKI Response in CML Remain Elusive
May 6, 2019, Cancer therapy advisor

Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib
May 6, 2019, PubMed

Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice
May 1, 2019, PubMed

TKI Discontinuation Safe in CML, But Patient Selection Is Key
May 1, 2019, OncLiveIncreased

Precision Tyrosine Kinase Inhibitor Dosing In Chronic Myeloid Leukemia
May 2019, Haematologica

Incidence of Second Malignancies in Patients With Chronic Myeloid Leukemia
April 30, 2019, Hematology Advisor

Dr. Shah on TKI Treatment Discontinuation in CML
April 24, 2019, OncLive

Researchers find drug-resistant gene for Gleevec
April 23, 2019, Korea Biomedical Review

Monitoring and Analysis of Chinese Chronic Myeloid Leukemia Patients Who Have Stopped Tyrosine Kinase Inhibitor Therapy
April 23, 2019, PubMed

Exploiting Unique Biological Features of Leukemia Stem Cells for Therapeutic Benefit
April 23, 2019, Stem Cells Jourrnal

Percent of Imported Pharmaceutical Ingredients Apparently Unchanged in 20 Years
April 19, 2019, Pharmacy Checker Blog

Reasons for TKI discontinuation ID'd in chronic myeloid leukemia
April 16, 2019, Medical Xpress

Rechallenge of ponatinib in chronic myeloid leukaemia after hepatotoxicity
April 2019,  Hong Kong Medical Journal

Earlier Molecular Testing May Boost CML Response
April 9, 2019, Clinical Oncology News

What is the best pharmacotherapeutic strategy for treating chronic myeloid leukemia in the elderly?
April 5, 2019, Expert Opinion

Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
April 3, 2019, The Oncologist

Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry)
April 2, 2019, PubMed

The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia
March 2019, Blood Advances

AACR Awards Scientific Honors and Lectures at 2019 Annual Meeting. Dr. Sawyers is being honored for his research into the mechanisms of drug resistance to treatments. 
March 30, 2019, Targeted Oncology

13 physicians named America’s Top Doctors for 2019
March 29, 20119, Augusta University     

MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia
March 28, 2019, PubMed

Chronic Myelogenous Leukemia: Impact of Chromosomal Aberrations on Disease Progression
March 28, 2019, Cancer Therapy Advisor

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia
March 27, 2019,  British Journal of Haematology

Suboptimal molecular response to tyrosine kinase inhibition associated with acquisition of a T240A ABL1 kinase domain mutation in a patient with chronic myeloid leukemia
March 26,  2019, Experimental Oncology

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs
March 26, 2019, PubMed

TKI Discontinuation Criteria Established in Updated NCCN CML Guideline
March 23, 2019, OncLive

How 'sleeper cell' cancer stem cells are maintained in chronic myelogenous leukemia
March 21, 2019, Medical Xpress

Jabbour Reviews TKI Options in Case Study of Chronic Phase CML
March 21, 2019, Targeted Oncology

OSU Research Paves Way for New Source for Leukemia Drug
March 20, 2019, The Skammer

Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation
March 16, 2019, PubMed

Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
March 14, 2019, Leukemia

Genetically encoded sensor isolates hidden leukemic stem cells
March 12, 2019, Medical Xpress

Roman Reigns Reveals Type of Leukemia He Had on New Episode of WWE Chronicle
March 12, 2019, Pro wresling

Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities
March 8, 2019, Dovepress

Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the STOP IMAPED study
March 6, 2019, PubMed

Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling
March 6, 2019, PubMed

A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib
March 5, 2019, PubMed

Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors
March 4, 2019, PubMed

Deep Analysis of BCR-ABL Transcripts Predicts Tyrosine Kinase Inhibitor Response in CML
February 28, 2019, Cancer Therapy Advisor

Dr. Jorge Cortes - Renowned clinical investigator selected as director for the Georgia Cancer Center
February 27, 2019, Augusta University   

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice
February 27, 2019, Haematologica

You Don’t Look Sick: ‘I’ve had cancer for 12 years but people tell me I’m lucky’
February 24, 2019, METRO.co.uk

Risk of Hospitalization Remains High for Survivors of Childhood Leukemia
February 21, 2019, Oncology Nurse Advisor

Mesa Explores Role of Interferon in Evolving MPN Treatment Paradigm
February 20, 2019, OncLivePatients

Optimal Time Points for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis on the Basis of European LeukemiaNet Recommendations in Chronic Myeloid Leukemia
February 20, 2019, PubMed

With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
February 19, 2019, Cancer Therapy Advisor

Bio-Rad's Digital PCR Kit Receives Industry First FDA Clearance
February 18, 2019, SelectScience

From Terminal Cancer to Twenty-Four Year Survivor
February 2019.  Coping with cancer

CML Patient Story: A 20-Year Survivor Shares His Clinical Trial Experience     VIDEO
February 13, 2019, Patient Power

Targeted Therapy Pioneers Slamon and Druker Awarded Sjoberg Prize
February 7, 2019, Targeted Oncology

Tests suggest scientists achieved 1st ‘in body’ gene editing
February 7, 2019, AP news

'Accidental discoveries': Cancer medications may have other uses 
February 5, 2019, The Chronicle

Physiologically based pharmacokinetic modeling to supplement nilotinib pharmacokinetics and confirm
dose selection in pediatric patients 
February 4, 2019, PubMed

Bosutinib: Management of Adverse Events in Chronic Myeloid Leukemia
January 23, 2019, Cancer Therapy Advisor

Treatment-Free Remission in CML: the US Perspective
January 15, 2019, Current Hematologic Malignancy Report

Indian firms can now access China's cancer drug market
Jan 11, 2019, The Times of India

Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study
January 10, 2019, Haematologica

smiR-302 cluster inhibits angiogenesis and growth of K562 leukemia cells by targeting VEGFA
January 8, 2019, Dovepress

An Expert Review of ASH 2018 CML News       VIDEO
January 7, 2019,  Patient Power

Coping With Loss: Requiem for a Beloved Mentor
January 7, 2019, OncLive

Bristol-Myers Squibb’s Sprycel® tablets now approved for pediatric patients 
January 6, 2019, Bio Spectrum Asia Edition

Harnessing the Power of Patients
January 4, 2019, Cure

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
January 3, 2019, Journal of Hematology & Oncology

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
January 3, 2019, PubMed

ddPCR Brings Confidence to Leukemia Monitoring
January 3, 2019, Technology Networks

Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
December 27, 2018, Journal of Hematology & Oncology

Targeting Functional Noncoding RNAs in CML With Cas9
December 19, 2018, Cancer Therapy Advisor

EU Panel Backs Dasatinib for Pediatric Ph+ ALL
December 17, 2018, OncLive

CML-IT-MOS: clinical characteristics of CML patients not included in clinical trials    VIDEO
December 17, 2018, VJHemOnc – Video Journal of Hematological Oncology

Generic vs. branded imatinib for CP-CML: a multicenter, observational study   VIDEO
December 17, 2018, VJHemOnc – Video Journal of Hematological Oncology

Conception, Pregnancy Possible During TKI Therapy for Chronic Myeloid Leukemia
​December 13, 2018,  Oncology Nurse Advisor

CML News From ASH: Patient Advocate Perspective
December 16, 2018, CML Advocates Network

Addressing Off-Target Effects of TKIs in Pediatric CML
December 10, 2018, OncLive

EUTOS Long-Term Survival Score Outperforms Sokal in TKI-Treated CML         
December 7, 2018, Cancer Therapy Advisor

LZTR1 is a regulator of RAS ubiquitination and signaling 
December 7, 2018, Science Mag

​​Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV 
December 4, 2018, NCBI

CML hematopoietic stem cells expressing IL-1RAP can be targeted by chimeric antigen receptor (CAR)-engineered T cells December 4, 2018, American Association for Cancer Research

Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients
December 2, 2018, Nature

Generic Imatinib Compared With Gleevec in CP-CML: Patient Outcomes Across 3 Countries
December 1, 2018, Cancer Therapy Advisor

Targeted Therapy for Leukemia: How These Groundbreaking Treatments Work
November 19, 2018,  25abc

The impact of chronic myeloid leukemia on employment: the French prospective study
November 17, 2018, PubMed

Translating research to cures: an intergenerational survivorship story      VIDEO
November 16, 2018, AtlanticLIVE

Possible Achilles' Heel of Leukemia Stem Cells
November 16, 2018, Technology Networks

Silent fight: One local woman's funding battle for cancer treatment
November 15, 2018, Windu

Novel predictor of treatment-free remission in CML
November 13, 2018, Thelimbic

Prototype Intervention Increased Adherence to TKIs in CML
November 13, 2018, Cancer Therapy Advisor  

Inclusion of data on treatment discontinuation in the Tasigna® product monograph approved by Health Canada for CML patients who achieve a sustained molecular response(i)
November 13, 2018, Cision

First quantitative diagnostic test validated for Treatment-Free Remission for Eligible Patients with Ph+ CML-CP Treated with Tasigna® Cleared by Health Canada
November 13, 2018, MolecularMD

2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML
November 12, 2018, Cancer Therapy Advisor

Connie J. Eaves, PhD, FRS, to Give Honorary Lecture at 2018 ASH Annual Meeting
November 10, 2018, ASCO POST

Expert reaks down data with TKI Discontinuation  in CML
November 9, 2018, OncLive

Study Offers Further Support to Long-Term Treatment-Free Remission in CML
November 9, 2018, JCCN360
 
Efficacy, safety must guide treatment sequencing decisions in chronic myeloid leukemia
November 7, 2018, HemOncToday

Epigenetic regulation of HOTAIR in advanced chronic myeloid leukemia
November 5 2018, Dovepress
 
Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor
November 3, 2018, BMC Endocrine Desorders
             
Imatinib Determined the Most Cost-Effective Frontline TKI for Chronic Myeloid Leukemia
November 2, 2018, Cancer Therapy Advisor

Emerging Agents, TKI Discontinuation Focal Points of CML Research
October 29, 2018, OncLive
​​
Devils’ Boyle says cancer is in remission
​October 24, 2018, TSN

Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
October 23, 2018, PubMed

Chronic Myeloid Leukemia Treatment Industry Is Booming Across the Globe Explored in Latest Research
October 19, 2018, India Reporter
​ 
Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
October 17, 2018, Cancer Therapy Advisor

​​New Combo for Chronic Myeloid Leukemia Shows Activity In Vitro
October 16, 2018, Cancer Therapy Advisor

Treatment-Free Remission Test Offers “Paradigm-Shifting” Value in CML
October 15, 2018, Journal of  Clinical Pathways

Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
October 15, 2018, Cancer Therapy Advisor

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
October 12, 2018,  PubMed

Dr. Radich on Compliance to NCCN Guidelines in CML       VIDEO
October 11, 2018, OncLive
​​
Dasatinib in Chronic Myeloid Leukemia Linked to Higher Healthcare Costs
October 10, 2018, Cancer Therapy Advisor

A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease
October 9, 2018, PubMed

Mel Mann, MBA, M.Ed
October 8, 2018, Patient Power

​​Treatment-Free Remission Feasible in Select Patients With CML
October 5, 2018, Targeted Oncology

​​​Dr. Radich on Treatment Discontinuation in CML Off Trial       VIDEO
September 27, 2018, OncLive

Practice Patterns of Physician Treatment for Pediatric Chronic Myeloid Leukemia (CML)
September 26, 2018,  PubMed

First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis
September 25, 2018, Dovepress

Recent Data Support TKI Discontinuation in Patients With CML
September 24, 2018,  OncLive

More than medicine - how support groups help leukaemia patients
September 24, 2018, Malaysiakini

Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML
​September 24, 2018, Cancer Therapy Advisor 

UK CML Patient Conference 2018 (22 Sept): Video Recordings Now Available
​September 22, 2018, CML Support

Taking the shortcut to frontline treatment
September 17, 2018, Fred Hutch

Asciminib: overcoming TKI resistance and reducing toxity in CML  (Dr. Timothy Hughes)     VIDEO
September 14, 2018, VJHemOnc – Video Journal of Hematological Oncology

Asciminib plus traditonal TKIs for chronic phase CML (Dr. Giuseppe Saglio)      VIDEO
September 13, 2018, VJHemOnc – Video Journal of Hematological Oncology

Tools for Coping With Weight Gain/Loss During Cancer Treatment               VIDEO
September 13, 2018, Patient Power

The Curious Case Of Gleevec Pricing
September 12, 2018, Forbes

New combination treatment targets pre-leukemia stem cells
September 12, 2018, Science Daily

Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia
September 11, 2018, Cancer Therapy Advisor

Knight Cancer Research Building opens new era in cancer research
September 7, 2018,  OHSU

Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era
September 5, 2018, PubMed

Nivolumab to control molecular response in chronic myeloid leukemia
September 2018, Leukemia Research

Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: The PEARL observational study
August 2018, Experimental Hematology

Dr. Sweet Discusses TKI Discontinuation in CML
August 31, 2018, OncLive

Looking Beyond Overall Survival in Chronic Myeloid Leukemia
August 30, 2018, OncLive

Chronic Myeloid Leukemia: Selecting Patients for TFR
August 30, 2018, OncLive

Dr. Hobbs Discusses the Treatment Landscape of CML
August 24, 2018, OncLive

TFR - a new treatment goal of CP-CML patients? with Dr. Delphine Rea?  VIDEO
August  2018, iCMLf

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
August 23, 2018, ACS Publications

Chronic Myeloid Leukemia: Understanding Loss of Response               VIDEO
August 20, 2018, OncLive

Cancer Research UK gives $4m funding to Glasgow Uni CML project
August 16, 2018, pharmaphorum

Relatives of Patients With Myeloid Blood Cancers May be at Two-Fold Risk for Disease
August 14, 2018, Cure Today

The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia
August 12, 2018,  PubMed

Polypharmacy and Cancer
August 10, 2018, Cancer Therapy Advisor

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia
August 9, 2018, PubMed

Time of Response to TKI Therapies May Influence Patient Outcomes in CML
August 9, 2018, Cancer Therapy Advisor

Second-Generation TKIs May Be Effective After First-Line Imatinib Failure in Pediatric CML
August 9, 2018, Cancer Therapy Advisor

The Real-World Role for Second-Line Ponatinib in CML Is Still Evolving
August 7, 2018, Cancer Therapy Advisor

When to Switch Therapy in Chronic Myeloid Leukemia           VIDEO
August 2,2018, OncLive

Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study
August 2018, Springer Link

An Overview of Chronic Myeloid Leukemia   VIDEO
July 19, 2018, OncLive

Research Indicates Imatinib Is Effective in Pediatric Patients With Chronic Phase CML
July 19, 2018, Cancer Therapy Advisor

Chinese Hit Movie ‘Dying to Survive’ Injects Urgency in Drug-Price Push
July 17, 2018, The Wall Street Journal

Dr. Pinilla-Ibarz Discusses Advancements in CML   VIDEO
July 16, 2018, OncLive

Expert Discusses the Discontinuation of TKIs in Treatment Landscape of CML
July 14, 2018, OncLive

2-Year Consolidation with Nilotinib Leads to High Rate of Treatment-Free Remission in CML
July 10, 2018, Cancer Therapy Advisor

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
July 6, 2018, ClinicalTrials.gov

RecurrenceFree Survival May B-e Sustainable After De-Escalation or Stoppage of TKI Therapy in CML
July 6, 2018, Cancer Therapy Advisor

EC approves expanded indication for Sprycel
July 6, 2018, thepharmaletter

Dasatinib Approved in Europe for Pediatric Ph+ Chronic Phase CML
July 5, 2018,  OncLive

Patients could be spared life-long leukaemia treatment, clinical trial finds
June 27, 2018,  University of Liverpool

Quebec City medical community mourning cycling death of promising physician
June 26, 2018, CBC

Low-Dose Dasatinib for Chronic-Phase CML Safe, Effective With Fewer Adverse Events
June 25, 2018, OncologyNurseAdvisor

ENESTfreedom Study Reports Durable Treatment-Free Remission in Chronic Myeloid Leukemia After 96 Weeks
June 25, 2018, Cancer Therapy Advisor

Discontinuing treatment and predicting relapse in CML          VIDEO
June 21, 2018, VJHemOnc – Video Journal of Hematological Oncology

New Drug May Be a Game Changer for Chronic Myeloid Leukemia Patients 
June 20, 2018, Oncology Times

OHSU Cancer Biologist Receives International Science Award
June 19, 2018, Portland Patch

Preeminent cancer biologist Brian Druker, M.D.,  receives international science award
June 19, 2018, OHSU News

Allogenic Stem Cell transplantation for CML in the TKI era: population based data from the Swedish CML registry
June 15, 2018, EHA learning center

Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey (China)
June 15, 2018, PubMed

Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey
June 15, 2018, Dovepress

Timothy Hughes - The importance of achieving early molecular response in CML VIDEO
June 15, 2018, VJHemOnc – Video Journal of Hematological Oncology
 
Timothy Hughes - Physicians must perform molecular monitoing regularly for successful outcomes in CML VIDEO
June 15, 2018, VJHemOnc – Video Journal of Hematological Oncology
 
Timothy Hughes - Chronic Myeloid Leukaemia (CML) News (part 1 – Treatment free remission) VIDEO
June 15, 2018, Leukaemia Care

Timothy Hughes - Chronic Myeloid Leukaemia (CML) News (part 2 – New drugs -ABL001) VIDEO
June 15, 2018, Leukaemia Care

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
June 12, 2018, NCBI
 
Strengthen healthcare with branded generics
June 8, 8 The Hindu Business Line

Present results and future perspectives in optimizing chronic myeloid leukemia therapy
June 2018, Haematologica

Dr. Patterson Discusses the Use of TKIs in Pediatric CML   VIDEO
June 6, 2016, OncLive

​ASCO 2018 - Susan Branford about Applications for Next-Generation Sequencing       VIDEO
June 3, 2018, QIAGEN

Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML
June 3, 2018, Cancer Therapy Advisor

Long-term treatment-free remission achievable for chronic myeloid leukemia
June 3, 2018, Healio

Bosutinib May Be Effective As First-Line Therapy in Chronic-Phase Chronic Myeloid Leukemia
June 3, 2018, Cancer Therapy Advisor

New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy
June 2, 2018, PR Newswire

CML Horizons 2018. SUN09 ABL001 Ascitinib trials. (Dr. Delphine Rea)    ​ VIDEO
May 28, 2018, CML Advocates Network

Chronic Myeloid Leukemia and Gastrointestinal Cancer Risk—In the Clinic
May 29, 2018, Cancer Therapy Advisor

Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient–Physician Perspective
June 2018, Clinical Lymphoma, Myeloma & Leukemia

Rare Case of Gaucher Disease and Chronic Myeloid Leukemia Reported in Spain­­­­­­
May 23, 2018, Gaucher disease News

Pediatric CML: Life-Long Considerations With TKI Therapy
May 22, 2018, Cancer Therapy Advisor

Actor Charlie Schlatter takes positive approach to fighting rare cancer
May 18, 2018, abc7

Right-to-Try Laws: Let's Move Beyond the Rhetoric
May 15, 2018, OncLIve

If You're Struggling To Become A Mother, This Is For You
May 13, 2018, MindBodyGreen

Ponatinib shows promise for chronic myeloid leukemia in chronic phase
May 12, 2018, Healio

Tasigna – Atherosclerosis
May 11, 2018, US Recall News 

Study: TKI Discontinuation Should Be Considered in Patients With CML Achieving Deep Molecular Response
May 8, 2018,  Journal of Clinical Pathways

Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study
May 7, 2018, PubMed

Deep Molecular Response May Allow TKI-therapy Discontinuation in Chronic Myeloid Leukemia
May 7, 2018, Cancer Therapy Advisor  

Low-dose Dasatinib May Be Effective as Frontline Therapy in Chronic-phase Chronic Myeloid Leukemia
May 7, 2018, Cancer Therapy Advisor

Nilotinib May Improve Rate of Deep Molecular Response in Chronic Myeloid Leukemia
May 7, 2018,  Cancer Therapy Advisor

Cardiovascular Health Considerations When Using Tyrosine Kinase Inhibitors
May 4, 2018, JNCCN360

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
May 4, 2018,   The Lancet Oncology

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group
May 3, 2018, PubMed

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia
May 3, 2018,  PubMed

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
May 2018, The Lancet Oncology   

'Getting pregnant could kill me': Roz Purcell's sister Rachel reveals struggle with chronic myeloid leukaemia
April 30, 2018, Irish Mirror

Northern Ireland mother who bravely delayed cancer treatment until her children were born
April 26, 2018, Belfast Telegraph

Following FDA Approvals, CML Pipeline Has Challenges
​April 24, 2017, OncLive

CML by Dr. Isabelle Bence-Bruckler, The Ottawa Hospital, Canada          VIDEO
April 21, 2018, The Canadian CML Network

Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia
April 13, 2018, PubMed

Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
April 12, 2018, PubMed

Eligibility for Cancer Drug Trials May Be Too Narrow
April 12, 2018,  Medpage Today
 
Bosutinib in chronic myeloid leukemia: patient selection and perspectives
April 9, 2018,  Dove Medical Press  

Pharma Dollars Appear to Sway Oncologist Rx Habits
April 9, 2018,  Medpage Today

FDA announces further approvals for nilotinib, blinatumomab
April 9, 2018, medwireNews

1-year Imatinib or Nilotinib Therapy Not Associated with Cardiotoxity in CML
April 9, 2018, Oncology Nurse Advisor

Risk of Secondary Cancers With CML Linked to Disease, Not Treatment
April 6, 2018, Oncology Nurse Advisor

Fresh Focus on Second Primary Cancers
April 5, 2018, OncLive

Dr. Mauro Discusses Updates in CML       VIDEO
April 2, 2018, OncLive    

Identifying Treatment Failure in Patients With Chronic Myeloid Leukemia
April 2, 2018, Cancer Therapy Advisor

Tasigna Lawsuits Mount, as Plaintiff in Washington State Accuses Novartis of Failing to Warn that Leukemia Drug Had Been Linked to Atherosclerosis-Related Conditions, Bernstein Liebhard LLP Reports
March 28, 2018, PR Newswire

Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia
March 25, 2018, PubMed

Analyst 'would not be surprised' to see Takeda retry Iclusig in first-line CML
March 25, 2018, The Pharma Letter

Tony Hunter receives Pezcoller Foundation-AACR International Award
March 23, 2018,  EurekAlert

Tasigna cleared for use in children with rare leukemia
March 23, 2018, PharmaTimes  

FDA Approves Nilotinib for Pediatric Chronic Myeloid Leukemia
March 22, 2018, Oncology Nursing News  

Ponatinib Maintains Benefit in Chronic-Phase CML at 5 Years
March 22, 2018, OncLive

Takeda Announces Publication of Final Data from ICLUSIG® (ponatinib) Pivotal Phase 2 PACE Trial in Blood
March 22, 2018, Boston Business Journal  

Publication of Final Data from ICLUSIG (ponatinib) Pivotal Phase 2 PACE Trial
March 22, 2018, Drug Discovery & Development

Assessment of BCR-ABL1 fusion transcripts and their association with response to imatinib treatment in chronic myeloid leukemia patients
March 21, 2018, Indian Journal of Medical and Paediatric Oncology

Ivermectin Induces Apoptosis Through Mitochondrial Dysfunction in CML Cells
March 13, 2018, Cancer Therapy Advisor  

Patients with Chronic Myeloid Leukemia at Increased Risk of Secondary Cancers
​March 13, 2018, Cancer Therapy Advisor

Molecular Response and Sokal Score Associated with Treatment-free Remission Duration in CML
​March 13, 2018, Cancer Therapy Advisor

CML: Managing TKI-Related Toxicity To Yield the Best Outcomes
March 12, 2018 , Cancer Therapy Advisor  

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
March 8, 2018, Current Treatment Options in Oncology

Disability need not define achievement, Hernández says
March 8 2018 , Cornel Chronicle

City of Hope working on potential leukemia breakthrough | ABC7    VIDEO
March 8, 2018, ABC7Second-line

Ponatinib Shows Promise for Rare Ovarian Cancer Type that Affects Young Women
March 8, 2018,  Oncology Nursing News

Drug could improve treatment of CML, team says
March 7, 2018, Hematology Times

New Drug Appears Promising Against Chronic Myelogenous Leukemia
March 6, 2018, City of Hope

Second-line Nilotinib May Lead to Treatment-Free Remission in Chronic Phase CML
March 5, 2018, Oncology Nurse Advisor

Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia
March 5, 2018, Nature Medicine

Dasatinib: A Safe and Effective Option for Pediatric CML
March 5, 2018, Cancer Therapy Advisor

City of Hope Study Published in Nature Medicine Reports on Promising New Drug to Fight Chronic Myelogenous Leukemia
March 5, 2018, BusinessWire
 
Leukemia Drug  (Iclusig -ponatinib) Shows Promise in Rare Ovarian Cancer Type
March 3, 2018, Cure Today
 
Dr. Cortes Discusses TKI Cessation in CML       VIDEO
March 2, 2018, OncLive
 
Bosutinib Nears EU Approval for Frontline Ph+ CML
February 26, 2018, OncLive

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
February 26, 2018, Nature

Treatment-Free Remission Assessed After Nilotinib Discontinuation in CML
February 26, 2018, Monthly Prescribing Reference

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
February 22, 2018, PubMed

Pediatric CML: Imatinib Effective in the Front Line
February 22, 2018, Cancer Therapy Advisor

Treatment-free remission of chronic myeloid leukemia possible after second-line nilotinib
February 20, 2018,  2 minute medicine

Treating Cancer: Tackling Drug Resistance
February 20. 2018, Technology Network

Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia
February 2018, Clinical Lymphoma, Myeloma & Leukemia

Pediatric CML: Imatinib Effective in the Front Line
February 19, 2018, Cancer Therapy Advisor

Experience with dasatinib and nilotinib use in pregnancy
February 17, 2017,  Sage Journals

Therapy-free remission in chronic myeloid leukemia: possible mechanism.
February 15, 2018, PubMed
​
Systems pharmacological analysis of mitochondrial cardiotoxicity induced by selected tyrosine kinase inhibitors.
February 14, 2018, PubMed

Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase.
February 13, 2018, PubMed

​What you need to know about chronic myeloid leukaemia
February 8, 2018, star2.com

Kantarjian, Prat: There's a better model for cancer research in U.S.
February 3, 2018, Houston Chronicle

Chronic Myeloid Leukemia: Choosing A TKI
February 1, 2018, Cancer Therapy Advisor
 
Treatment-Free Remission and Preventing Cardiotoxicity: The Future of CML Care
January 31, 2018, AJMC.com Managed Markets Network

Practical management of toxicities associated with bosutinib  in patients with Philadelphia chromosome-positive chronic myeloid leukemia
January 27, 2018, Annals of Oncology

Dasatinib dose management for the treatment of chronic myeloid leukemia
January 25, 2018, Cancer       

Rationale for TKI Therapy in Relapsed CML
January 22, 2018,  Targeted  Oncology

Relapsed CML: Mutation Testing and Therapy Choices
January 22, 2018,  Targeted  Oncology

Treatment Approach for Relapsed CML
January 22, 2018,  Targeted  Oncology

Dose Reduction and Third-Line Therapy for CML
January 22, 2018,  Targeted  Oncology

Nilotinib Can Be Discontinued in Some Patients with Chronic Myelogenous Leukemia
January 19, 2018,  National Cancer Institute

A New $500 Blood Test Could Detect Cancer Before Symptoms Develop
January 18, 2018, Forbes

CML Update From News at ASH 2017 ( Dr. Michael Mauro)
​January 17, 2018, Patient Power

Could Switching to Interferon Avoid an Abnormal Ovarian Response in CML?
January 17, 2018, Cancer Therapy Advisor

Bernstein Liebhard LLP Investigating Potential Tasigna Lawsuits on Behalf of Individuals Who Allegedly Developed Arteriosclerosis and Associated Complications While Undergoing Leukemia Treatment with This Medication
Jan 16, 2018, PRNewswire

Deep sea creatures provide a guiding light in the quest to develop cancer therapies
January 9, 2018, Science Daily
​
Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience)
January 6, 2018, PubMed

BCR-ABL1 Levels Can Predict Sustained Deep Molecular Response in CML
January 5, 2018, Cancer Network

Targeting cancer by sabotaging the DNA repair seesaw
January 5, 2018, Brinkwire
​
Thomas Joseph Reilly, ex-King Kullen exec, dies at 74
January 4, 2018, Newsday 

Pepsi® or Coke®? Influence of acid on dasatinib absorption
January 1, 2018, PublMed

​Dasatinib increases endothelial permeability leading to pleural effusion
January 2018, European Respiratory Journal

                  See News on CML (after 2020)                  
                                 See Archives ( 2019-2018)
                  See Archives ( 2017-2016)
                  See Archives ( 2015-2014)
                  See Archives ( 2013-2012)
                                 See Archives before 2012